Entre f\u00e9vrier 2025 et janvier 2026, plus de 840 000 patients ont \u00e9t\u00e9 trait\u00e9s par agonistes des r\u00e9cepteurs du GLP-1 (aGLP-1) en France. Sur cette p\u00e9riode, 2 801 effets ind\u00e9sirables ont \u00e9t\u00e9 signal\u00e9s, dont 515 graves. Environ un cas sur trois concernait un traitement du diab\u00e8te de type 2 et un cas sur trois un traitement du surpoids ou de l\u2019ob\u00e9sit\u00e9 pour le contr\u00f4le du poids, le reste relevant d\u2019indications non pr\u00e9cis\u00e9es ou non autoris\u00e9es. Les effets ind\u00e9sirables les plus fr\u00e9quents \u00e9taient des troubles gastro-intestinaux (naus\u00e9es, vomissements, diarrh\u00e9es, douleurs abdominales), parfois responsables d\u2019hospitalisation, ainsi que des cas de pancr\u00e9atite, effets d\u00e9j\u00e0 connus et mentionn\u00e9s dans les documents d\u2019information des m\u00e9dicaments.<\/p>\n
Le rapport met en \u00e9vidence un m\u00e9susage des aGLP-1 \u00e0 des fins de perte de poids en dehors des indications encadr\u00e9es. Trente-six signalements d\u2019effets ind\u00e9sirables li\u00e9s \u00e0 une utilisation non appropri\u00e9e ont \u00e9t\u00e9 recens\u00e9s, dont 17 cas graves, touchant plut\u00f4t des personnes jeunes. Dans deux tiers des cas, les m\u00e9dicaments avaient \u00e9t\u00e9 obtenus hors des circuits officiels (internet, entourage, achat \u00e0 l\u2019\u00e9tranger) et, dans plus de 90 % des cas, les doses utilis\u00e9es \u00e9taient trop \u00e9lev\u00e9es ou augment\u00e9es trop rapidement par rapport aux recommandations. Parmi les cas graves, cinq pancr\u00e9atites aigu\u00ebs ont \u00e9t\u00e9 rapport\u00e9es. Les autorit\u00e9s rappellent que les aGLP-1 sont des m\u00e9dicaments n\u00e9cessitant une prescription m\u00e9dicale, une d\u00e9livrance en pharmacie et un suivi m\u00e9dical, et que tout recours \u00e0 des circuits non officiels expose \u00e0 des risques graves pour la sant\u00e9.<\/p>\n
Une surveillance renforc\u00e9e de certains effets ind\u00e9sirables est en cours. Des cas de pancr\u00e9atites, d\u00e9j\u00e0 connues et mentionn\u00e9es dans les notices et r\u00e9sum\u00e9s des caract\u00e9ristiques du produit, ont de nouveau \u00e9t\u00e9 observ\u00e9s, dont deux cas possiblement responsables de d\u00e9c\u00e8s. Les m\u00e9decins sont invit\u00e9s \u00e0 informer les patients sur les sympt\u00f4mes \u00e9vocateurs de pancr\u00e9atite aigu\u00eb et \u00e0 assurer un suivi r\u00e9gulier pour rep\u00e9rer pr\u00e9cocement les signes d\u2019effets ind\u00e9sirables graves et adapter la prise en charge. Des cas de carences nutritionnelles et de malnutrition ont \u00e9galement \u00e9t\u00e9 signal\u00e9s, et des recommandations de prise en charge ont \u00e9t\u00e9 \u00e9labor\u00e9es par les centres sp\u00e9cialis\u00e9s dans l\u2019ob\u00e9sit\u00e9. Le rapport souligne enfin un risque d\u2019interaction avec des m\u00e9dicaments \u00e0 marge th\u00e9rapeutique \u00e9troite, notamment certains anticoagulants, pour lesquels la dose doit \u00eatre pr\u00e9cis\u00e9ment ajust\u00e9e et fait l\u2019objet d\u2019une surveillance m\u00e9dicale renforc\u00e9e. Ces \u00e9l\u00e9ments pr\u00e9sentent un enjeu de s\u00e9curit\u00e9 sanitaire, de bon usage du m\u00e9dicament et de r\u00e9gulation des circuits d\u2019approvisionnement, en particulier pour les usages de perte de poids hors cadre m\u00e9dical.\u00a0(contenu r\u00e9sum\u00e9 par l’IA)Lire la Suite<\/a>\u200b<\/p>","protected":false},"excerpt":{"rendered":" Entre f\u00e9vrier 2025 et janvier 2026, plus de 840 000 patients ont \u00e9t\u00e9 trait\u00e9s par agonistes des r\u00e9cepteurs du GLP-1 (aGLP-1) en France. Sur cette p\u00e9riode, 2 801 effets ind\u00e9sirables […]<\/p>\n","protected":false},"author":1,"featured_media":3852,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[7],"tags":[63,227],"class_list":["post-20150","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicaments-et-produits-de-sante","tag-ansm","tag-ia"],"_links":{"self":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts\/20150","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20150"}],"version-history":[{"count":0,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts\/20150\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/media\/3852"}],"wp:attachment":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20150"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20150"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20150"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}